Prevalence of aflatoxin B1 in liver biopsies of proven hepatocellular carcinoma in India determined by an in-house immunoperoxidase test
1 Department of Microbiology, Faculty of Medicine, Dr ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600 113, India 2 Medical Gastroenterology Unit of the Government General Hospital, Chennai 600 001, India 3 Medical and Surgical Gastroenterology Unit of t...
Gespeichert in:
Veröffentlicht in: | Journal of medical microbiology 2007-11, Vol.56 (11), p.1455-1459 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | 1 Department of Microbiology, Faculty of Medicine, Dr ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600 113, India
2 Medical Gastroenterology Unit of the Government General Hospital, Chennai 600 001, India
3 Medical and Surgical Gastroenterology Unit of the Government Stanley Medical College and Hospital, Chennai 600 001, India
4 Government Kilpauk Medical College and Hospital, Chennai 600 029, India
Correspondence K. G. Murugavel murugavel{at}yrgcare.org
Received 4 January 2007
Accepted 29 June 2007
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death in the world. The incidence of HCC in India is reportedly low and varies from 0.2 to 1.9 %. Aflatoxins, secondary metabolites produced by Aspergillus flavus and Aspergillus parasiticus , are potent human carcinogens implicated in HCC. The prevalence of aflatoxin B1 (AFB1) as co-carcinogen was analysed using an in-house immunoperoxidase test in 31 liver biopsies and 7 liver-resection specimens from histopathologically proven HCC, and in 15 liver biopsies from cirrhosis patients (control group). Serum was tested for hepatitis B and C serological markers using commercial assays, and for AFB1 using an in-house ELISA with a sensitivity of 1 ng ml –1 for AFB1. In spite of positive AFB1 immunostaining in HCC cases, all serum specimens, from both HCC and the control groups, were AFB1-negative. There were 18 (58.1 %) HCC cases that revealed AFB1 in liver biopsies; 68.8 % ( n =11) of non-B non-C hepatitis cases with HCC and 46.1 % ( n =6) of the hepatitis B surface-antigen-positive subjects were positive for AFB1. Out of the two hepatitis B/hepatitis C virus co-infected cases, one was positive for AFB1. Of seven tumour-resection samples, six were positive for AFB1. Only one case revealed AFB1 in the non-tumour area of the resected material. Thus AFB1 staining was significantly associated with tumour tissue ( P =0.03). Aflatoxins proved to have a significant association with HCC in this peninsular part of the subcontinent. The impact seems to be a cumulative process, as revealed by the AFB1 deposits in HCC liver tissue, even though the serum levels were undetectable.
Abbreviations: AFB1, aflatoxin B1; DAB, 3'3'-diaminobenzidine tetrahydrochloride; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma. |
---|---|
ISSN: | 0022-2615 1473-5644 |
DOI: | 10.1099/jmm.0.47151-0 |